Observational Study of Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange Therapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Clotting Disorder Due to Plasma Exchange Therapy
- Sponsor
- Hannover Medical School
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Thrombin clotting time
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
Plasma exchange is a frequently used therapy in many antibody-mediated disorders, such as humoral rejection after kidney transplantation. Treatment frequency is adjusted to daily measured fibrinogen blood levels to prevent bleeding complications. However, data about the correlation of fibrinogen blood levels and function of the coagulation system during plasma exchange therapy is scarce. In the present study we examine blood fibrinogen levels and coagulation factors as well as thrombin clotting time in patients under plasma exchange therapy.
Investigators
Julius Schmidt
MD
Hannover Medical School
Eligibility Criteria
Inclusion Criteria
- •plasma exchange therapy due to humoral rejection after kidney transplantation
Exclusion Criteria
- •hereditary coagulopathy
- •chronic liver disease (Child C)
- •therapeutic anticoagulation
- •malnutrition (BMI\<17.5)
Outcomes
Primary Outcomes
Thrombin clotting time
Time Frame: Baseline, daily measurement until hospital discharge (avarage hospital stay: 10 days)
Daily measurement after initiation of plasma exchange therapy until treatment course is finished